

WOCKHARDT'S TRANSFORMATION

Amongst the Top 3 Indian Pharma Companies


with

95% Growth in Profit After Tax at Rs.378 crores

61% Growth in EBITDA at Rs. 502 crores

35% Growth in Revenues at Rs. 1426 crores

in 1st Quarter of 2012-13



	Q1FY13		Q1FY12	FY12
	Apr - Jun 2012		Apr-Jun 2011	
	Rsc	Gwth Y-O-Y	Rsc	Rsc
Sales	1,426	35%	1,053	4,614
EBITDA	502	61%	312	1,440
EBITDA Margins %	35%		30%	31%
PAT	378	95%	194	343
PAT Margins	27%		18%	7%
Adjusted PAT	383	97%	194	947
PAT Margins %	27%		18%	21%
EPS (Adj. PAT)	35.0	97%	17.8	86.5

Wockhardt Limited, the Pharmaceutical and Biotechnology major, delivered 95% increase in Profit After Tax at Rs.378 crores in 1st Quarter of financial year 2012-13. The EBITDA at Rs.502 crores grew by 61% and represented 10th consecutive quarter of sequential growth. This sustained EBITDA and PAT performance, both in terms of value and margins, now ushers Wockhardt amongst the Top 3 Best Performing Indian Pharma companies.

Consolidated revenues grew by 35% to Rs.1,426 Crores over the corresponding quarter of Financial Year 2011-12. This represented 5th consecutive quarter of sequential growth in consolidated revenues. Wockhardt's US and EU operations have been the major contributor in its growth and the momentum continued in this quarter as they contributed to 71% of consolidated revenues.

US business recorded a spectacular growth of 78% (45% on \$ basis) compared to the corresponding quarter of Financial Year 2011-12. The US business launched the authorized generic version of Stalevo® for which it had received FTF status earlier and 2 OTC products during the quarter.

The UK business recorded a growth of 31% (11% on £ basis) compared to the corresponding quarter of Financial Year 2011-12 in an otherwise stagnant market. In the quarter the UK and Irish markets launched the generic Atorvastatin, which is expected to be a key product for both UK and Irish businesses.

Wockhardt's R&D continued its multidisciplinary research and patent filings across its 3 R&D centers worldwide employing 578 scientists. The company now has a total of 164 Patents granted and has filed for a total of 1585 Patents Globally. It has received the Government of India and Pharmexcil award for maximum patents filing for 3 years in a row. The company markets 475 products in the regulated markets manufactured in its India, USA, UK and Ireland facilities.

Late Dr. Abid Hussain, India's former ambassador to USA and a non-executive director on the board of Wockhardt passed away on June 21st 2012. Wockhardt has appointed Dr. Sanjaya Baru, a noted economist and former media advisor to the Prime Minister of India and Mr. D S Brar, ex CEO and MD of Ranbaxy, as non-executive directors on the board.

Wockhardt recently concluded the divestment of its Nutrition business to Danone for Rs.1280 crores. This has significantly improved the balance sheet position for the company and its Net Debt to Equity ratio now stands below 1.

About Wockhardt:

Wockhardt is a high-technology intensive global pharmaceutical and biotechnology company with multi-disciplinary and innovative R&D programmes. It has 3 research centres globally and manufacturing facilities across India, USA, UK and Ireland. Wockhardt has a significant presence in USA, Europe and India, with 75% of its global revenues coming from international businesses. With a large pool of Patents and Intellectual Property knowhow, Wockhardt is home to 578 scientists, of whom 80 are doctorates. In all, Wockhardt has 164 Patents granted worldwide. In biotechnology research, it has built a competent 'Concept to Market' capabilities in all facets of development and manufacture of recombinant biopharmaceuticals. Wockhardt boasts of a multi-ethnic workforce of more than 8000 people from 14 different nationalities.